Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL10385406 | 0.79 | SNCA (0.42) | HTR2AHTR2CALDH1A1KDM4E | |
| SCHEMBL7006014 | 0.77 | ABCB1 (0.46) | ABCB1HTR2AHTR2CL3MBTL1ALDH1A1 | |
| Bromide SCHEMBL5444015 | 0.76 | HTR1A (0.43) | HTR2AL3MBTL1LTA4H | |
| SCHEMBL2288984 | 0.76 | TUBB4A (0.47) | ABCB1L3MBTL1ALDH1A1CYP1A2CYP2D6 | |
| Bromide SCHEMBL1604414 | 0.75 | SNCA (0.56) | ALDH1A1CYP1A2CYP2D6CYP2C19MEN1 | |
| Bromide SCHEMBL1681292 | 0.73 | POLB (0.50) | L3MBTL1ALDH1A1CYP1A2CYP2D6CYP2C19 | |
| Bromide SCHEMBL9954598 | 0.72 | LTA4H (0.52) | ABCB1L3MBTL1ALDH1A1MAPK1SIGMAR1 | |
| Bromide SCHEMBL7249345 | 0.72 | PLA2G2A (0.45) | ALDH1A1CYP1A2CYP2D6CYP2C19MEN1 | |
| Hydrochloric Acid SCHEMBL995949 | 0.72 | LTA4H (0.55) | ALDH1A1CYP1A2CYP2D6CYP2C19MEN1 | |
| Iodide SCHEMBL3971492 | 0.72 | LTA4H (0.55) | ALDH1A1CYP1A2CYP2D6CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940811-B1 | HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2014-02-26 | — | — | EP | disclosed |
| EP-1940809-B1 | TETRAZOL DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2013-12-25 | — | — | EP | disclosed |
| US-8183271-B2 | Tetrazole derivatives and their use for the treatment of cardiovascular diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-7998988-B2 | Biphenyl compounds useful in the treatment or prevention of cardiovascular disorders | BAYER SCHERING PHARMA AKTIENGELLSCHAFT (DE) | 2011-08-16 | — | — | US | disclosed |
| US-20090227640-A1 | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases | BAYER HEALTHCARE AG (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090215843-A1 | Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-08-27 | — | — | US | disclosed |
| EP-1940811-A1 | HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1940809-A1 | TETRAZOL DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007045370-A1 | TETRAZOL DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045366-A1 | HETEROCYCLIC COMPOUNDS WITH CARBOXYL ISOSTERE GROUPS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227640-A1 | Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases | TNNI3, PC, TNNT2 | ABCB1 713/4885HTR2A 2615/4885HTR2C 1831/4885 |
| US-20090215843-A1 | Tetrazole Derivatives and Their Use for the Treatment of Cardiovascular Diseases | TNNI3, TNNT2, FABP3 | ABCB1 430/4885HTR2A 4432/4885HTR2C 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.